Literature DB >> 17584137

The biology of cholecystokinin and gastrin peptides.

Jens F Rehfeld1, Lennart Friis-Hansen, Jens P Goetze, Thomas V O Hansen.   

Abstract

Cholecystokinin (CCK) and gastrin together constitute a family of homologous peptide hormones, which are both physiological ligands for the gastrin/CCK-B receptor, whereas the CCK-A receptor binds only sulfated CCK-peptides. CCK peptides are mainly produced in small intestinal endocrine I-cells and in cerebral neurons. CCK peptides regulate pancreatic enzyme secretion and growth, gallbladder contraction, intestinal motility, satiety and inhibit gastric acid secretion. Moreover, they are potent neurotransmitters in the brain and the periphery. CCK peptides are derived from proCCK and have the bioactive heptasequence -Tyr(SO4)-Met-Gly-Trp-Met-Asp-Phe-NH2 as their C-terminus. The dominant forms in plasma are CCK-58, CCK-33, CCK-22 and CCK-8, whereas CCK-8 is the major transmitterform. Due to scarcity of specific assays, knowledge about CCK in disease is still limited. Gastrin peptides are mainly synthetized in antroduodenal G-cells, from where they are released to blood to regulate gastric acid secretion and mucosal growth. Small amounts are synthetized further down the intestinal tract, in the foetal pancreas, in a few cerebral and peripheral neurons, in the pituitary gland and in spermatozoes. Gastrin peptides are derived from progastrin and all have the C-terminal bioactive hexasequence -Tyr (SO4)-Gly-Trp-Met-Asp-Phe-NH2. The major gastrin forms in tissue and plasma are gastrin-34 and gastrin-17, but also gastrin-71, -14 and -6 have been identified. Gastrin peptides are secreted in excessive amounts from gastrinomas and are expressed at lower levels in bronchogenic, colorectal, gastric, ovarian and pancreatic cancers. A carcinogenetic significance of gastrin peptides remains, however, to be proven.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584137     DOI: 10.2174/156802607780960483

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  60 in total

1.  The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.

Authors:  Helen H Wang; Piero Portincasa; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2016-01-12       Impact factor: 4.686

Review 2.  The Histochemistry and Cell Biology omnium-gatherum: the year 2015 in review.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2016-02-15       Impact factor: 4.304

3.  The Src kinase Yes is activated in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters, but not pancreatic growth factors, which stimulate its association with numerous other signaling molecules.

Authors:  Veronica Sancho; Bernardo Nuche-Berenguer; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2012-05-19

4.  PKCθ activation in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters and growth factors is needed for stimulation of numerous important cellular signaling cascades.

Authors:  Veronica Sancho; Marc J Berna; Michelle Thill; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2011-07-23

5.  Non-sulfated cholecystokinin-8 increases enteric and hindbrain Fos-like immunoreactivity in male Sprague Dawley rats.

Authors:  Amged I Dafalla; Thaer R Mhalhal; Kenneth Hiscocks; John Heath; Ayman I Sayegh
Journal:  Brain Res       Date:  2018-12-17       Impact factor: 3.252

6.  Gastrointestinal hormones/neurotransmitters and growth factors can activate P21 activated kinase 2 in pancreatic acinar cells by novel mechanisms.

Authors:  Bernardo Nuche-Berenguer; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2015-05-12

7.  Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.

Authors:  N Irwin; P Frizelle; I A Montgomery; R C Moffett; F P M O'Harte; P R Flatt
Journal:  Diabetologia       Date:  2012-07-20       Impact factor: 10.122

8.  Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis.

Authors:  Yue Chen; Laureano D Asico; Shuo Zheng; Van Anthony M Villar; Duofen He; Lin Zhou; Chunyu Zeng; Pedro A Jose
Journal:  Hypertension       Date:  2013-09-09       Impact factor: 10.190

Review 9.  Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.

Authors:  Marc J Berna; Jose A Tapia; Veronica Sancho; Robert T Jensen
Journal:  Curr Opin Pharmacol       Date:  2007-11-09       Impact factor: 5.547

Review 10.  An update on pancreatic pathophysiology (do we have to rewrite pancreatic pathophysiology?).

Authors:  Heinz F Hammer
Journal:  Wien Med Wochenschr       Date:  2014-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.